Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 10/20 | 0.78 |
| ▸ | DRD3 | P35462 | 11/20 | 0.71 |
| ▸ | DRD4 | P21917 | 10/20 | 0.68 |
| ▸ | HTR1A | P08908 | 7/20 | 0.68 |
| ▸ | DRD1 | P21728 | 7/20 | 0.68 |
| ▸ | DRD5 | P21918 | 7/20 | 0.68 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.59 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.59 |
| ▸ | PRCP | P42785 | 1/20 | 0.59 |
| ▸ | EBP | Q15125 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8300543 | 0.92 | DRD3 (0.78) | DRD2DRD3DRD4HTR1ADRD1 | |
| SCHEMBL3454031 | 0.88 | DRD2 (1.00) | DRD2DRD3DRD4HTR1ADRD1 | |
| SCHEMBL29914667 | 0.88 | DRD2 (1.00) | DRD2DRD3DRD4HTR1ADRD1 | |
| SCHEMBL4827157 | 0.85 | DRD2 (0.87) | DRD2DRD3DRD4HTR1ADRD1 | |
| SCHEMBL7316143 | 0.83 | DRD3 (1.00) | DRD2DRD3DRD4HTR1ADRD1 | |
| SCHEMBL7354319 | 0.83 | DRD3 (0.80) | DRD2DRD3DRD4HTR1ADRD1 | |
| SCHEMBL6657019 | 0.83 | DRD3 (0.88) | DRD2DRD3DRD4HTR1ADRD1 | |
| SCHEMBL10274630 | 0.81 | DRD2 (0.69) | DRD2DRD3DRD4HTR1ADRD1 | |
| SCHEMBL19235999 | 0.81 | DRD2 (0.72) | DRD2DRD3DRD4HTR1ADRD1 | |
| SCHEMBL28322710 | 0.81 | DRD2 (0.52) | DRD2DRD3DRD4HTR1ADRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3083601-B1 | PIPERIDINE DERIVATIVES HAVING MULTIMODAL ACTIVITY AGAINST PAIN | ESTEVE PHARMACEUTICALS SA (ES) | 2020-09-09 | — | — | EP | disclosed |
| US-RE46117-E1 | Modulators of dopamine neurotransmission | TEVA PHARMACEUTICALS INTERNATIONAL GMBH (CH) | 2016-08-23 | — | — | US | disclosed |
| US-7417043-B2 | Modulators of dopamine neurotransmission | NEUROSEARCH SWEDEN AB (SE) | 2008-08-26 | — | — | US | disclosed |
| CN-100345833-C | Modulators of dopamine neurotransmission | CARLSSON RES AB (SE) | 2007-10-31 | — | — | CN | disclosed |
| US-20060135531-A1 | Modulators of dopamine neurotransmission | A. CARLSSON RESEARCH AB (SE) | 2006-06-22 | — | — | US | disclosed |
| CN-1255382-C | Novel modulators of dopamine neurotransmission | CARLSSON A RESEARCH AB (SE) | 2006-05-10 | — | — | CN | disclosed |
| CN-1765890-A | Modulators of dopamine neurotransmission | CARLSSON RES AB (SE) | 2006-05-03 | — | — | CN | disclosed |
| EP-1240142-B1 | NEW MODULATORS OF DOPAMINE NEUROTRANSMISSION | CARLSSON A RESEARCH AB (SE) | 2005-10-19 | — | — | EP | disclosed |
| US-6903120-B2 | A 4-(phenyl-N- alkyl)-piperidine derivatives for treatment of central nervous system disorders, Parkinson disease, anxiety, dyskinesias, dystonias, Tourette's disease, psychoses, hallucinoses, sleep disorder, autism | A. CARLSSON RESEARCH AB (SE) | 2005-06-07 | — | — | US | disclosed |
| EP-1428822-A2 | 1-phenylpiperazine derivative as modulators of dopamine neurotransmission | A. Carlsson Research AB (SE) | 2004-06-16 | — | — | EP | disclosed |
| US-20030139423-A1 | Modulators of dopamine neurotransmission | TEVA PHARMACEUTICALS INTERNATIONAL GMBH (CH) | 2003-07-24 | — | — | US | disclosed |
| CN-1420869-A | Novel modulators of dopamine neurotransmission | CARLSSON A RESEARCH AB (SE) | 2003-05-28 | — | — | CN | disclosed |
| EP-1240142-A1 | NEW MODULATORS OF DOPAMINE NEUROTRANSMISSION | A. Carlsson Research AB (SE) | 2002-09-18 | — | — | EP | disclosed |
| WO-2001046145-A1 | NEW MODULATORS OF DOPAMINE NEUROTRANSMISSION | A. CARLSSON RESEARCH AB (SE) | 2001-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060135531-A1 | Modulators of dopamine neurotransmission | SLC6A3, BRS3, CHRNA3 | DRD2 18/4885DRD3 5/4885DRD4 26/4885 |
| US-20030139423-A1 | Modulators of dopamine neurotransmission | OPRD1, OPRK1, OPRM1 | DRD2 16/4885DRD3 8/4885DRD4 30/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.